At Nastech, we leverage our focus on formulation science and expertise in manufacturing intranasal dosage forms to rapidly move from concept to the clinic.

We have experience working with therapeutics spanning a wide range of physicochemical properties. For example, Nastech has developed intranasal formulations of active pharmaceutical ingredients (APIs) with molecular weights varying from small molecules to peptides and complex proteins.

This process utilizes both in vitro and in vivo analyses to identify and select formulations with desirable attributes such as increased drug permeability and unchanged safety profile of the molecule. For example, one component of this process is our cell-based screening process that is designed to measure the ability of different formulations to reversibly open tight junctions with minimal or no impact on cell viability.

Through this process and in concert with our tight junction research programs we have identified a library of compounds that directly and specifically affect the tight junction between cells in nasal tissues in a manner mimicking natural processes. We have used these compounds to create formulations that are capable of increasing drug permeability.